Ra Capital Management buys $52,800,459 stake in Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) : Ra Capital Management scooped up 439,300 additional shares in Nektar Therapeutics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 3,664,154 shares of Nektar Therapeutics which is valued at $52,800,459.Nektar Therapeutics makes up approximately 5.39% of Ra Capital Management’s portfolio.

Other Hedge Funds, Including , D.a. Davidson reduced its stake in NKTR by selling 500 shares or 8.2% in the most recent quarter. The Hedge Fund company now holds 5,600 shares of NKTR which is valued at $80,696.Comerica Bank boosted its stake in NKTR in the latest quarter, The investment management firm added 1,639 additional shares and now holds a total of 138,177 shares of Nektar Therapeutics which is valued at $1,890,261. Nektar Therapeutics makes up approx 0.02% of Comerica Bank’s portfolio.Dimensional Fund Advisors Lp reduced its stake in NKTR by selling 136,827 shares or 30.24% in the most recent quarter. The Hedge Fund company now holds 315,619 shares of NKTR which is valued at $4,317,668.Blackrock Investment Management reduced its stake in NKTR by selling 28,565 shares or 4.98% in the most recent quarter. The Hedge Fund company now holds 544,904 shares of NKTR which is valued at $6,974,771. Nektar Therapeutics makes up approx 0.01% of Blackrock Investment Management’s portfolio.Mcdonald Capital Investors Incca reduced its stake in NKTR by selling 4,500 shares or 28.13% in the most recent quarter. The Hedge Fund company now holds 11,500 shares of NKTR which is valued at $142,600. Nektar Therapeutics makes up approx 0.01% of Mcdonald Capital Investors Incca’s portfolio.

Nektar Therapeutics closed down -0.03 points or -0.21% at $13.94 with 11,95,037 shares getting traded on Monday. Post opening the session at $13.74, the shares hit an intraday low of $13.7 and an intraday high of $14.14 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Nektar Therapeutics reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.36. The company had revenue of $36.30 million for the quarter, compared to analysts expectations of $31.50 million. The company’s revenue was down -39.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.06 EPS.

Many Wall Street Analysts have commented on Nektar Therapeutics. Nektar Therapeutics was Initiated by Aegis Capital to “Buy” on Nov 8, 2016. Nektar Therapeutics was Resumed by Brean Capital to “Buy” on Sep 30, 2016.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.